News
The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...
Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could ...
22h
GlobalData on MSNMadrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...
13h
Zacks.com on MSNMadrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.
16h
Zacks.com on MSNViking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...
It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...
Fresh & Ready Foods, LLC, recalled a few of their ready-to-eat products, including sandwiches and other snack items, over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results